ATE544451T1 - Pharmazeutisch aktive isoindolin-derivate - Google Patents

Pharmazeutisch aktive isoindolin-derivate

Info

Publication number: ATE544451T1
Authority: AT; Austria
Prior art keywords: pharmaceutically active; isoindoline derivatives; active isoindoline; derivatives; oxoisoindoline
Prior art date: 1999-11-12

Application number

AT10176390T

Other languages

English (en)

Inventor

Hon-Wah Man

George W Muller

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2000-11-09

Publication date

2012-02-15

2000-11-09 Application filed by Celgene Corp filed Critical Celgene Corp

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE544451T1 publication Critical patent/ATE544451T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Biotechnology (AREA)
Physical Education & Sports Medicine (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT10176390T 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate ATE544451T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16516899P	1999-11-12	1999-11-12
US59034400A	2000-06-08	2000-06-08
US09/708,199 US6667316B1 (en)	1999-11-12	2000-11-08	Pharmaceutically active isoindoline derivatives

Publications (1)

Publication Number	Publication Date
ATE544451T1 true ATE544451T1 (de)	2012-02-15

Family

ID=27389110

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AT06009632T ATE506058T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate
AT10176390T ATE544451T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate
AT00977095T ATE357913T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch-aktive isoindolin-derivate
AT10176420T ATE544452T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT06009632T ATE506058T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AT00977095T ATE357913T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch-aktive isoindolin-derivate
AT10176420T ATE544452T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate

Country Status (19)

Country	Link
US (1)	US6667316B1 (de)
EP (4)	EP1698334B1 (de)
JP (1)	JP5116201B2 (de)
CN (1)	CN1325497C (de)
AT (4)	ATE506058T1 (de)
AU (2)	AU782409B2 (de)
CA (1)	CA2392081C (de)
CY (2)	CY1107610T1 (de)
DE (1)	DE60034139T2 (de)
DK (2)	DK2263669T3 (de)
ES (4)	ES2381174T3 (de)
FI (1)	FI119931B (de)
HK (2)	HK1049158A1 (de)
MX (1)	MXPA02004793A (de)
NO (2)	NO323633B1 (de)
NZ (1)	NZ519459A (de)
PT (2)	PT2263669E (de)
SI (1)	SI1228071T1 (de)
WO (1)	WO2001034606A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429221B1 (en)	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US6518281B2 (en) *	1995-08-29	2003-02-11	Celgene Corporation	Immunotherapeutic agents
JP4214537B2 (ja) *	1996-08-12	2009-01-28	セルジーンコーポレーション	新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7491634B2 (en) *	2006-04-28	2009-02-17	Asm International N.V.	Methods for forming roughened surfaces and applications thereof
CA2444704C (en)	2001-04-23	2012-07-10	University Of Virginia Patent Foundation	Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
US7153867B2 (en) *	2001-08-06	2006-12-26	Celgene Corporation	Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) *	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CN1668296A (zh)	2002-05-17	2005-09-14	细胞基因公司	使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
AU2003228509B2 (en)	2002-10-15	2008-06-26	Celgene Corporation	Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CA2504263A1 (en) *	2002-10-31	2004-05-21	Celgene Corporation	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
US7776907B2 (en)	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CN1735412A (zh)	2002-11-06	2006-02-15	细胞基因公司	利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
MXPA05004777A (es) *	2002-11-06	2005-07-22	Celgene Corp	Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
CA2506232A1 (en) *	2002-11-18	2004-06-03	Celgene Corporation	Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
MXPA05005161A (es) *	2002-11-18	2005-07-22	Celgene Corp	Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
ATE449081T1 (de)	2002-12-30	2009-12-15	Celgene Corp	Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
ZA200507322B (en) *	2003-03-06	2007-03-28	Celgene Corp	Selective cytokine inhibitory drugs for treating disorders of the central nervous system
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US7034052B2 (en) *	2003-03-12	2006-04-25	Celgene Corporation	7-Amido-isoindolyl compounds and their pharmaceutical uses
CN100427465C (zh) *	2003-03-12	2008-10-22	细胞基因公司	N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
ZA200507283B (en) *	2003-03-12	2007-03-28	Celgene Corp	N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
EP1613269B1 (de)	2003-04-04	2015-02-25	Incyte Corporation	Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
US7320992B2 (en) *	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2543132A1 (en) *	2003-10-23	2005-05-19	Celgene Corporation	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CA2563207A1 (en) *	2004-04-14	2005-11-24	Celgene Corporation	Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
AU2005234783A1 (en) *	2004-04-23	2005-11-03	Celgene Corporation	Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
BRPI0418801A (pt) *	2004-05-05	2007-10-16	Celgene Corp	métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit
MXPA06012701A (es) *	2004-05-05	2007-02-14	Celgene Corp	Metodo de utilizacion y composiciones que comprenden farmacos inhibidores de citocina selectivos para el tratamiento y manejo de enfermedades mieloproliferativas.
WO2006004191A1 (en) *	2004-07-05	2006-01-12	Astellas Pharma Inc.	Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7244759B2 (en) *	2004-07-28	2007-07-17	Celgene Corporation	Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP2008512378A (ja)	2004-09-03	2008-04-24	セルジーン・コーポレーション	置換複素環式化合物及びその使用
ZA200704251B (en) *	2004-10-28	2008-11-26	Celgene Corp	Methods and compositions using PDE4 modulators for treatment and management of central nervous injury
KR20070092276A (ko) *	2004-12-13	2007-09-12	셀진 코포레이션	Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2268279A1 (de) *	2008-03-24	2011-01-05	Celgene Corporation	Behandlung von psoriasis oder psoriatischer arthritis mit cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl}-3-oxoisoindolin-4-yl}carbonsäureamid
AU2009298888A1 (en) *	2008-09-23	2010-04-08	Georgetown University	1,2-benzisothiazolinone and isoindolinone derivatives
WO2010039538A2 (en)	2008-09-23	2010-04-08	Georgetown University	Flavivirus inhibitors and methods for their use
EP2395995A1 (de)	2009-02-10	2011-12-21	Celgene Corporation	Anwendungsverfahren und zusammensetzungen mit pde4-modulatoren zur behandlung, prävention und management von tuberkulose
US8952178B2 (en) *	2009-05-14	2015-02-10	Tianjin Hemay Bio-Tech Co., Ltd.	Thiophene derivatives
EP2690092B1 (de) *	2009-06-18	2016-03-16	Concert Pharmaceuticals Inc.	Deuterierte Isoindolin-1,3-dion-Derivate als PDE4 und TNF-Alpha-Hemmer
AR078581A1 (es) *	2009-10-09	2011-11-16	Celgene Corp	Procesos para la preparacion de compuestos 2-(1-feniletil)isoindolin-1-ona
CN102770412A (zh) *	2009-12-22	2012-11-07	细胞基因公司	(甲基磺酰基)乙基苯异吲哚啉衍生物及其治疗应用
CA2794096A1 (en)	2010-04-07	2011-10-13	Celgene Corporation	Methods for treating respiratory viral infection
US20110318741A1 (en)	2010-06-15	2011-12-29	Schafer Peter H	Biomarkers for the treatment of psoriasis
EP2663292B9 (de) *	2011-01-10	2017-11-08	Celgene Corporation	Orale dosierungsformen von cyclopropancarbonsäure {[2- (1s) -1- (3-ethoxy-4-methoxy-phenyl] -2-methansulfonyl-ethyl} -3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amid
WO2012096884A1 (en) *	2011-01-10	2012-07-19	Celgene Corporation	Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
WO2012097116A2 (en)	2011-01-14	2012-07-19	Celgene Corporation	Isotopologues of isoindole derivatives
WO2012121988A2 (en)	2011-03-07	2012-09-13	Celgene Corporation	Methods for treating diseases using isoindoline compounds
US9428472B2 (en)	2011-08-16	2016-08-30	Georgetown University	Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
AU2012308663B2 (en) *	2011-09-14	2017-06-08	Amgen (Europe) GmbH	Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
US8981117B2 (en)	2012-09-14	2015-03-17	Celgene Corporation	Processes for the preparation of isoindole compounds and isotopologues thereof
US20170087129A1 (en)	2014-05-16	2017-03-30	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
US10300042B2 (en)	2014-06-23	2019-05-28	Celgene Corporation	Apremilast for the treatment of a liver disease or a liver function abnormality
EP3271330A1 (de) *	2015-03-19	2018-01-24	Cipla Limited	Verbessertes verfahren zur herstellung von apremilast
US10682336B2 (en)	2015-10-21	2020-06-16	Amgen Inc.	PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
HU231259B1 (hu)	2016-02-04	2022-06-28	Egyt Gyogyszervegyeszeti Gyar	Eljárás pomalidomide elõállítására
CA3034785C (en) *	2016-08-22	2022-11-15	Shijiazhuang Sagacity New Drug Development Co., Ltd.	Pde4 inhibitor
CN107698484B (zh) *	2017-11-13	2020-05-19	广东中科药物研究有限公司	一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (en)	2018-01-17	2019-07-25	Cadila Healthcare Limited	Pharmaceutical compositions for treatment of vitiligo
WO2019201255A1 (zh)	2018-04-17	2019-10-24	天津合美医药科技有限公司	异吲哚衍生物
CN110746376B (zh) *	2018-07-22	2024-04-30	上海星叶医药科技有限公司	苯并异硒唑酮胺类化合物及其制备方法和用途
CN110003084B (zh) *	2019-03-15	2022-08-02	华南师范大学	一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) *	2020-01-09	2023-01-17	常州大学	作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
KR20230157936A (ko) *	2020-12-14	2023-11-17	바이오테릭스, 인코포레이티드	Pde4 분해인자, 약제학적 조성물, 및 치료학적 적용
EP4310079A4 (de) *	2021-03-15	2024-10-30	Shenzhen Forward Pharmaceuticals Co., Limited	Östrogenrezeptorantagonist
CN114790164B (zh)	2021-08-13	2022-12-27	苏州璞正医药有限公司	一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
CN116354857B (zh) *	2023-03-01	2025-01-21	中国人民解放军海军军医大学	一种β-氨基砜及其衍生物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4173652A (en)	1976-12-18	1979-11-06	Akzona Incorporated	Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv)	1980-06-06	1984-08-06	Lekemedelsfabriken Medica Ab	Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en)	1987-03-04	1989-04-11	Ortho Pharmaceutical Corporation	Cinnamohydroxamic acids
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
US5463063A (en) *	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
US5605914A (en)	1993-07-02	1997-02-25	Celgene Corporation	Imides
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US5703098A (en) *	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
DE69610709T2 (de)	1995-07-26	2001-02-22	Pfizer Inc., New York	N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
WO1997024117A1 (en)	1996-01-02	1997-07-10	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
PT968182E (pt) *	1996-08-07	2004-08-31	Darwin Discovery Ltd	Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt
JP4214537B2 (ja)	1996-08-12	2009-01-28	セルジーンコーポレーション	新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
HUP0003761A3 (en) *	1997-07-31	2001-04-28	Celgene Corp Warren	Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

2000
- 2000-11-08 US US09/708,199 patent/US6667316B1/en not_active Expired - Lifetime
- 2000-11-09 PT PT10176420T patent/PT2263669E/pt unknown
- 2000-11-09 ES ES10176390T patent/ES2381174T3/es not_active Expired - Lifetime
- 2000-11-09 ES ES10176420T patent/ES2380574T3/es not_active Expired - Lifetime
- 2000-11-09 DE DE60034139T patent/DE60034139T2/de not_active Expired - Lifetime
- 2000-11-09 AT AT06009632T patent/ATE506058T1/de not_active IP Right Cessation
- 2000-11-09 AT AT10176390T patent/ATE544451T1/de active
- 2000-11-09 SI SI200030951T patent/SI1228071T1/sl unknown
- 2000-11-09 WO PCT/US2000/030770 patent/WO2001034606A1/en active IP Right Grant
- 2000-11-09 AU AU14780/01A patent/AU782409B2/en not_active Ceased
- 2000-11-09 CN CNB00818254XA patent/CN1325497C/zh not_active Expired - Fee Related
- 2000-11-09 EP EP06009632A patent/EP1698334B1/de not_active Expired - Lifetime
- 2000-11-09 DK DK10176420.7T patent/DK2263669T3/da active
- 2000-11-09 AT AT00977095T patent/ATE357913T1/de active
- 2000-11-09 ES ES06009632T patent/ES2363933T3/es not_active Expired - Lifetime
- 2000-11-09 EP EP10176390A patent/EP2255801B1/de not_active Expired - Lifetime
- 2000-11-09 NZ NZ519459A patent/NZ519459A/en not_active IP Right Cessation
- 2000-11-09 EP EP10176420A patent/EP2263669B1/de not_active Expired - Lifetime
- 2000-11-09 CA CA002392081A patent/CA2392081C/en not_active Expired - Fee Related
- 2000-11-09 EP EP00977095A patent/EP1228071B8/de not_active Expired - Lifetime
- 2000-11-09 AT AT10176420T patent/ATE544452T1/de active
- 2000-11-09 JP JP2001536553A patent/JP5116201B2/ja not_active Expired - Fee Related
- 2000-11-09 PT PT00977095T patent/PT1228071E/pt unknown
- 2000-11-09 DK DK00977095T patent/DK1228071T3/da active
- 2000-11-09 MX MXPA02004793A patent/MXPA02004793A/es active IP Right Grant
- 2000-11-09 ES ES00977095T patent/ES2282147T3/es not_active Expired - Lifetime
2002
- 2002-05-08 NO NO20022223A patent/NO323633B1/no not_active IP Right Cessation
- 2002-05-10 FI FI20020892A patent/FI119931B/fi not_active IP Right Cessation
2003
- 2003-02-05 HK HK03100819.6A patent/HK1049158A1/zh unknown
- 2003-07-30 HK HK03105496A patent/HK1053467A1/xx not_active IP Right Cessation
2005
- 2005-07-07 AU AU2005202964A patent/AU2005202964B2/en not_active Ceased
2007
- 2007-03-21 NO NO20071490A patent/NO336210B1/no not_active IP Right Cessation
- 2007-04-05 CY CY20071100487T patent/CY1107610T1/el unknown
2012
- 2012-04-26 CY CY20121100399T patent/CY1112707T1/el unknown

Also Published As

Publication number	Publication date
EP1698334A1 (de)	2006-09-06
CY1107610T1 (el)	2013-03-13
AU2005202964A1 (en)	2005-08-11
FI20020892A0 (fi)	2002-05-10
SI1228071T1 (sl)	2007-08-31
ATE544452T1 (de)	2012-02-15
JP2004500346A (ja)	2004-01-08
US6667316B1 (en)	2003-12-23
CA2392081A1 (en)	2001-05-17
EP2255801A1 (de)	2010-12-01
EP1228071B1 (de)	2007-03-28
ES2380574T3 (es)	2012-05-16
EP1228071A4 (de)	2002-12-04
ES2381174T3 (es)	2012-05-23
CN1325497C (zh)	2007-07-11
MXPA02004793A (es)	2003-10-14
EP1228071B8 (de)	2012-02-29
CA2392081C (en)	2010-01-05
AU2005202964B2 (en)	2007-11-22
ES2363933T3 (es)	2011-08-19
NZ519459A (en)	2003-11-28
JP5116201B2 (ja)	2013-01-09
PT2263669E (pt)	2012-04-23
NO20071490L (no)	2002-07-08
DK1228071T3 (da)	2007-08-06
FI20020892L (fi)	2002-06-20
ATE506058T1 (de)	2011-05-15
ES2282147T3 (es)	2007-10-16
EP2255801B1 (de)	2012-02-08
AU782409B2 (en)	2005-07-28
HK1049158A1 (zh)	2003-05-02
NO20022223L (no)	2002-07-08
DE60034139D1 (de)	2007-05-10
ATE357913T1 (de)	2007-04-15
NO336210B1 (no)	2015-06-15
EP2263669B1 (de)	2012-02-08
NO323633B1 (no)	2007-06-18
FI119931B (fi)	2009-05-15
EP1228071A1 (de)	2002-08-07
DK2263669T3 (da)	2012-04-23
CN1420889A (zh)	2003-05-28
NO20022223D0 (no)	2002-05-08
PT1228071E (pt)	2007-05-31
DE60034139T2 (de)	2007-12-06
EP2263669A1 (de)	2010-12-22
HK1053467A1 (en)	2003-10-24
AU1478001A (en)	2001-06-06
CY1112707T1 (el)	2016-02-10
EP1698334B1 (de)	2011-04-20
WO2001034606A1 (en)	2001-05-17

Publication	Publication Date	Title
ATE506058T1 (de)	2011-05-15	Pharmazeutisch aktive isoindolin-derivate
NO20002217D0 (no)	2000-04-28	Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
CO5580776A2 (es)	2005-11-30	Formulacion farmaceutica estable en solucion de oxaliplatino
DE60045168D1 (de)	2010-12-09	Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure
ES2084702T3 (es)	1996-05-16	Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
EA200500853A1 (ru)	2006-08-25	2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
DK3449934T3 (da)	2020-06-29	Behandling af glycogenlagringssygdom type II
WO2002019969A3 (en)	2002-07-11	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DE50005529D1 (de)	2004-04-08	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CY1107616T1 (el)	2013-03-13	Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
EA200101150A1 (ru)	2002-04-25	Раствор прукалоприда для перорального применения
SE9902742D0 (sv)	1999-07-20	New pharmaceutical formultion
IT1306706B1 (it)	2001-10-02	Articolatore perfezionato per la realizzazione di modelli in gesso.
DE69807200D1 (de)	2002-09-19	Inklusionskomplexe in waessriger loesung
DE60045878D1 (de)	2011-06-01	Pharmazeutisch aktive Isoindolin-Derivate
ITMO990002A0 (it)	1999-01-20	Articolatore per odontotecnica.
DK1086695T3 (da)	2005-04-25	Antivirale præparater omfattende yohimbin som aktivt princip
ATE302582T1 (de)	2005-09-15	Haartonikum mit l-arginin als wirkstoff
RU2000106182A (ru)	2002-01-27	Средство для лечения поражения кожи различной этиологии
IT1311630B1 (it)	2002-03-14	Perfezionamento ad una struttura di vassoio isotermico,particolarmente per la somministrazione delle vivande alle comunita'.
ES1043165Y (es)	2000-12-16	Contenedor ligero perfeccionado.
ITBO990038A0 (it)	1999-01-28	Pomata per la cura delle lesioni cutanee particolarmente delle ustioni .
ES1044269Y (es)	2000-09-01	Mesa camilla desmontable.
ES1043536Y (es)	2000-06-01	Calzado perfeccionado.
IT1316492B1 (it)	2003-04-22	Accessorio polifunzionale, particolarmente per la cura dell'acquario.